Biomea Fusion, Inc.
biomeafusion.comWhat Do They Do?
Develops oral small-molecule drug candidates for diabetes, obesity and other metabolic diseases.
10-K for FY2025, filed Mar 24, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 24, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$8.3MView ↗
- ▼ −60% (Loss)
- vs −$20.7M in Q2 FY2025
From broad pipeline to metabolic focus
The business has narrowed from developing covalent drug candidates for cancers and metabolic diseases to focusing on diabetes and obesity medicines; the company plans to seek partners for its oncology assets.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 24, 2026
Loading...
